Black Diamond Therapeutics, Inc.
139 Main Street, Suite 301
About Black Diamond Therapeutics, Inc.
Precision Cancer Medicines for Every Genetically-Defined Patient
Black Diamond Therapeutics: A Next-Wave Cancer Precision Medicine Company
Black Diamond Therapeutics has pioneered the development of selective medicines for patients with genetically-defined cancers driven by oncogenes activated by allosteric mutations.
The cornerstone of our approach derives from evolving trends in cancer clinical medicine. Genome-wide information – now routinely obtained from DNA testing of cancer patients – identifies clusters of uncharacterized genomic alterations. Today, new baskets of un-drugged oncogenic targets exist, leading to the identification of additional cancer patients in need of novel therapies.
Using our MAP platform, Black Diamond Therapeutics is pioneering new ways to functionally assess the mutational landscape of individual oncogenes – to discover and validate new targets, and to develop novel approaches to creating highly selective therapeutics.
29 articles with Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, announced the pricing of its initial public offering of 10,586,316 shares of common stock at a public offering price of $19.00 per share.
Company also announces CRISPR Therapeutics CEO Samarth Kulkarni, Ph.D., Joins its Board of Directors
Black Diamond Therapeutics to Present Preclinical Data on its Lead Product Candidate BDTX-189 at the European Society for Medical Oncology 2019
Black Diamond Therapeutics, Inc. announced that preclinical data defining the molecular mechanism for oncogenic activation of families of epidermal growth factor receptor allosteric mutations and showing activity of the Company's lead product candidate BDTX-189 will be presented at the European Society for Medical Oncology Congress 2019, taking place from September 27 to October 1, 2019 in Barcelona, Spain.
Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Christopher D. Roberts, Ph.D., as Chief Scientific Officer.
Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Thomas (Tommy) Leggett as Chief Financial Officer (CFO).
Team also strengthened with key hires in preclinical and clinical development, clinical operations, and finance to drive company's lead program into the clinic in 2020 and advance its pipeline and MAP platform
Black Diamond Therapeutics Presents Data From its Program Targeting Oncogenic Allosteric Mutations in EGFR for Glioblastoma as Late Breaker at the American Association for Cancer Research (AACR) Annual Meeting
Black Diamond Therapeutics, Inc. announced that data from its first-in-class program targeting a group of epidermal growth factor receptor allosteric mutants that drive glioblastoma multiforme will be presented at the American Association for Cancer Research Annual Meeting 2019.
Next-wave precision oncology company poised to advance multiple products into clinical development
Next-wave precision oncology company emerges from Versant’s Ridgeline Discovery Engine